Award
NIH Reporter #5R43NS134446-02
Gene Therapy for Idiopathic Parkinson's Disease
Recipient
Not Specified
Award Amount
$192,244.00
Ceiling
$192,244.00
Awarded
July 25, 2025
Identifier
5R43NS134446-02
NIH SBIR Phase 1 award for gene therapy development targeting Parkinson's Disease, amounting to $192,244, focusing on preclinical safety and efficacy.
Description
This is a NIH SBIR Phase 1 project focused on developing gene therapy for Parkinson's Disease, with a total award amount of $192,244. The project aims to optimize and validate gene therapy candidates, with a focus on safety and efficacy in preclinical models. The project start date is September 1, 2024, and end date is August 31, 2026.